Literature DB >> 18384631

Accuracy of life tables in predicting overall survival in patients after radical prostatectomy.

Jochen Walz1, Nazareno Suardi, Shahrokh F Shariat, Claudio Jeldres, Paul Perrotte, Markus Graefen, Hughes Widmer, Philippe Arjane, Luc Valiquette, Georg Hutterer, Fred Saad, Pierre I Karakiewicz.   

Abstract

OBJECTIVE: To test the accuracy of life tables (LT), the standard tool for predicting life-expectancy (LE), but the accuracy of which is unknown in patients with prostate cancer, where the 10-year LE is a widely accepted threshold for the delivery of definitive therapy. PATIENTS AND METHODS: We tested the accuracy of predictions of LE from LT in 9678 men treated with radical prostatectomy (RP) for prostate cancer. The predictions of LE from LT at 10 years after RP were compared to Kaplan Meier-derived 10-year survival values. Moreover, the accuracy of LT predictions was quantified in a Cox-regression using Harrell's concordance index. To control for the effect of prostate cancer mortality, analyses were repeated in a subset of 5955 patients with no evidence of disease recurrence. Additional stratification schemes were applied to control for age and comorbidity.
RESULTS: At RP, the median age was 64 years, the median Charlson Comorbidity Index (CCI) was 1 and the median LT-derived LE was 16 years. The median actuarial survival was not reached (mean 12.4 years). In the whole group the LT-predicted 10-year survival was 96.8%, vs an observed of 75.3%. In men with no disease recurrence the LT-predicted survival was 97.3%, vs 81.1% observed. After age and CCI stratification, LT overestimated the 10-year survival the most in those aged 65-69 years and in patients with CCI scores of >2.
CONCLUSION: The overestimation of LE can lead to overtreatment of prostate cancer, especially in those men who die early from other causes.

Entities:  

Mesh:

Year:  2008        PMID: 18384631     DOI: 10.1111/j.1464-410X.2008.07614.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  11 in total

1.  Prediction of mortality after radical prostatectomy by Charlson comorbidity index.

Authors:  Thomas J Guzzo; Paul Dluzniewski; Ryan Orosco; Elizabeth A Platz; Alan W Partin; Misop Han
Journal:  Urology       Date:  2010-09       Impact factor: 2.649

2.  Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study.

Authors:  Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson
Journal:  Urology       Date:  2014-09-26       Impact factor: 2.649

3.  Clinical and Demographic Factors Associated With Receipt of Non Guideline-concordant Initial Therapy for Nonmetastatic Prostate Cancer.

Authors:  Ann S Hamilton; Steven T Fleming; Dian Wang; Michael Goodman; Xiao-Cheng Wu; Jean B Owen; Mary Lo; Alex Ho; Roger T Anderson; Trevor Thompson
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339

4.  Impact of age at diagnosis on prostate cancer treatment and survival.

Authors:  Seth K Bechis; Peter R Carroll; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

5.  Consideration of comorbidity in risk stratification prior to prostate biopsy.

Authors:  Michael A Liss; John Billimek; Kathryn Osann; Jane Cho; Ross Moskowitz; Adam Kaplan; Richard J Szabo; Sherrie H Kaplan; Sheldon Greenfield; Atreya Dash
Journal:  Cancer       Date:  2013-04-25       Impact factor: 6.860

6.  Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.

Authors:  Pierre Lunardi; Guillaume Ploussard; Pascale Grosclaude; Mathieu Roumiguié; Michel Soulié; Jean Baptiste Beauval; Bernard Malavaud
Journal:  World J Urol       Date:  2016-07-21       Impact factor: 4.226

7.  Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.

Authors:  Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson
Journal:  Ann Intern Med       Date:  2013-05-21       Impact factor: 25.391

8.  Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients.

Authors:  Angela B Mariotto; Zhuoqiao Wang; Carrie N Klabunde; Hyunsoon Cho; Barnali Das; Eric J Feuer
Journal:  J Clin Epidemiol       Date:  2013-09-10       Impact factor: 6.437

Review 9.  Challenges of managing elderly men with prostate cancer.

Authors:  Gautam G Jha; Vidhu Anand; Ayman Soubra; Badrinath R Konety
Journal:  Nat Rev Clin Oncol       Date:  2014-05-13       Impact factor: 66.675

10.  Impact of comorbidities at diagnosis on prostate cancer treatment and survival.

Authors:  Katarina Luise Matthes; Manuela Limam; Giulia Pestoni; Leonhard Held; Dimitri Korol; Sabine Rohrmann
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.